Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a t-cell infiltrate in the bone marrow

Dhruv Bansal; Kiran Vij; Gue Su Chang; Christopher A. Miller; John F. Dipersio; Ravi Vij; Sharon E. Heath; Peter Westervelt; John S. Welch; Todd A. Fehniger

doi:10.3324/haematol.2017.184168

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a t-cell infiltrate in the bone marrow

Dhruv Bansal, Kiran Vij, Gue Su Chang, Christopher A. Miller, John F. Dipersio, Ravi Vij, Sharon E. Heath, Peter Westervelt, John S. Welch, Todd A. Fehniger

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Original language	English
Pages (from-to)	e270-e273
Journal	Haematologica
Volume	103
Issue number	6
DOIs	https://doi.org/10.3324/haematol.2017.184168
State	Published - Jun 3 2018

Access to Document

10.3324/haematol.2017.184168

Cite this

Bansal, D., Vij, K., Chang, G. S., Miller, C. A., Dipersio, J. F., Vij, R., Heath, S. E., Westervelt, P., Welch, J. S., & Fehniger, T. A. (2018). Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a t-cell infiltrate in the bone marrow. Haematologica, 103(6), e270-e273. https://doi.org/10.3324/haematol.2017.184168

@article{ee28f127ee494a88bed03749d321d462,

title = "Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a t-cell infiltrate in the bone marrow",

author = "Dhruv Bansal and Kiran Vij and Chang, {Gue Su} and Miller, {Christopher A.} and Dipersio, {John F.} and Ravi Vij and Heath, {Sharon E.} and Peter Westervelt and Welch, {John S.} and Fehniger, {Todd A.}",

note = "Funding Information: Funding: support was also provided by NCI Leukemia SPORE (P50 CA171963) and the Genomics of AML Program Project grant (P01 CA101937). TAF is supported by R01CA205239. We thank Greg Malnassy, Nichole Helton, and the Washington University Tissue Procurement Core for sample storage and sample preparation. We thank Timothy Schappe for assistance with sample collection. We thank all BMT/Leukemia treatment teams and all patients who elected to participate in this clinical trial. Correspondence: [email protected]/[email protected] doi:10.3324/haematol.2017.184168 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.",

year = "2018",

month = jun,

day = "3",

doi = "10.3324/haematol.2017.184168",

language = "English",

volume = "103",

pages = "e270--e273",

journal = "Haematologica",

issn = "0390-6078",

number = "6",

}

Bansal, D, Vij, K, Chang, GS, Miller, CA , Dipersio, JF , Vij, R, Heath, SE, Westervelt, P, Welch, JS & Fehniger, TA 2018, 'Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a t-cell infiltrate in the bone marrow', Haematologica, vol. 103, no. 6, pp. e270-e273. https://doi.org/10.3324/haematol.2017.184168

TY - JOUR

T1 - Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a t-cell infiltrate in the bone marrow

AU - Bansal, Dhruv

AU - Vij, Kiran

AU - Chang, Gue Su

AU - Miller, Christopher A.

AU - Dipersio, John F.

AU - Vij, Ravi

AU - Heath, Sharon E.

AU - Westervelt, Peter

AU - Welch, John S.

AU - Fehniger, Todd A.

N1 - Funding Information: Funding: support was also provided by NCI Leukemia SPORE (P50 CA171963) and the Genomics of AML Program Project grant (P01 CA101937). TAF is supported by R01CA205239. We thank Greg Malnassy, Nichole Helton, and the Washington University Tissue Procurement Core for sample storage and sample preparation. We thank Timothy Schappe for assistance with sample collection. We thank all BMT/Leukemia treatment teams and all patients who elected to participate in this clinical trial. Correspondence: [email protected]/[email protected] doi:10.3324/haematol.2017.184168 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

PY - 2018/6/3

Y1 - 2018/6/3

UR - http://www.scopus.com/inward/record.url?scp=85048055103&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.184168

DO - 10.3324/haematol.2017.184168

M3 - Comment/debate

C2 - 29567774

AN - SCOPUS:85048055103

SN - 0390-6078

VL - 103

SP - e270-e273

JO - Haematologica

JF - Haematologica

IS - 6

ER -

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a t-cell infiltrate in the bone marrow

Access to Document

Other files and links

Cite this